Multiparametric magnetic resonance imaging in the detection of prostate cancer

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 186, Issue 3, 2014, Pages 238-246

  Durmus, T ^a   Baur, A ^a   Hamm, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

imaging sequences; MR imaging; neoplasms; prostate

Indexed keywords

ADULT; ALGORITHMS; HUMANS; IMAGE ENHANCEMENT; IMAGE-GUIDED BIOPSY; MALE; MULTIMODAL IMAGING; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE;

EID: 84894252774     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0034-1365937     Document Type: Review

References (56)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin: 2012; 62 10 29 10.3322/caac.20138
2. Wilt T. J., Brawer M. K., Jones K. M. et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med: 2012; 367 203 213 10.1056/NEJMoa1113162
3. Zelefsky M. J., Chan H., Hunt M. et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol: 2006; 176 1415 1419 S0022-5347(06)01371-1 [pii] 10.1016/j.juro.2006.06.002 (Pubitemid 44307191)
4. Padhani A. R. Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging: 2011; 11 S27 S37 10.1102/1470-7330.2011.9007
5. Beyersdorff D., Darsow U., Stephan C. et al. MRI of prostate cancer using three different coil systems: image quality, tumor detection, and staging. Fortschr Röntgenstr: 2003; 175 799 805 10.1055/s-2003-39929 (Pubitemid 36806763)
6. Nakashima J., Tanimoto A., Imai Y. et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology: 2004; 64 101 105 10.1016/j.urology.2004.02.036 S0090429504003231 [pii] (Pubitemid 38887587)
7. Beyersdorff D., Taupitz M., Winkelmann B. et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology: 2002; 224 701 706 (Pubitemid 34919801)
8. Barrett T., Vargas H. A., Akin O. et al. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology: 2012; 263 751 757 10.1148/radiol.12112100
9. Rosenkrantz A. B., Kopec M., Kong X. et al. Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging. J Magn Reson Imaging: 2010; 31 1387 1394 10.1002/jmri.22172
10. Kaji Y., Kurhanewicz J., Hricak H. et al. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology: 1998; 206 785 790 10.1148/radiology.206.3.9494502 (Pubitemid 28128531)
11. Franiel T., Stephan C., Erbersdobler A. et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding - multiparametric MR imaging for detection and biopsy planning. Radiology: 2011; 259 162 172 radiol.10101251 [pii] 10.1148/radiol.10101251
12. Turkbey B., Pinto P. A., Mani H. et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection - histopathologic correlation. Radiology: 2010; 255 89 99 255/1/89 [pii] 10.1148/radiol.09090475
13. Barentsz J. O., Richenberg J., Clements R. et al. ESUR prostate MR guidelines 2012. Eur Radiol: 2012; 22 746 757 10.1007/s00330-011-2377-y
14. Turkbey B., Aras O., Karabulut N. et al. Diffusion-weighted MRI for detecting and monitoring cancer: a review of current applications in body imaging. Diagn Interv Radiol: 2012; 18 46 59 10.4261/1305-3825.DIR.4708-11.2
15. Yagci A. B., Ozari N., Aybek Z. et al. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Interv Radiol: 2011; 17 130 134 10.4261/1305-3825.DIR.3399-10.1
16. Haider M. A., van der Kwast T. H., Tanguay J. et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol: 2007; 189 323 328 189/2/323 [pii] 10.2214/Am J Roentgenol.07.2211 (Pubitemid 47195916)
17. Kim C. K., Park B. K., Lee H. M. et al. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol: 2007; 42 842 847 10.1097/RLI.0b013e3181461d21 00004424-200712000-00007 [pii] (Pubitemid 350126566)
18. Oto A., Yang C., Kayhan A. et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. Am J Roentgenol: 2011; 197 1382 1390 10.2214/ajr.11.6861
19. Turkbey B., Shah V. P., Pang Y. et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology: 2011; 258 488 495 radiol.10100667 [pii] 10.1148/radiol.10100667
20. Hambrock T., Somford D. M., Huisman H. J. et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology: 2011; 259 453 461 10.1148/radiol.11091409
21. Turkbey B., Bernardo M., Merino M. J. et al. MRI of localized prostate cancer: coming of age in the PSA era. Diagn Interv Radiol: 2012; 18 34 45 10.4261/1305-3825.DIR.4478-11.1
22. Durmus T., Vollnberg B., Schwenke C. et al. Dynamic Contrast Enhanced MRI of the Prostate: Comparison of Gadobutrol and Gd-DTPA. Fortschr Röntgenstr: 2013; 185 862 868 10.1055/s-0033-1335892
23. Franiel T., Hamm B., Hricak H. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol: 2011; 21 616 626 10.1007/s00330-010-2037-7
24. Ocak I., Bernardo M., Metzger G. et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am J Roentgenol: 2007; 189 849 189/4/849 [pii] 10.2214/Am J Roentgenol.06.1329
25. Kozlowski P., Chang S. D., Jones E. C. et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis - correlation with biopsy and histopathology. J Magn Reson Imaging: 2006; 24 108 113 10.1002/jmri.20626
26. Noworolski S. M., Vigneron D. B., Chen A. P. et al. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging: 2008; 26 1071 1080 10.1016/j.mri.2008.01.033 S0730-725X(08)00057-X [pii]
27. Delongchamps N. B., Rouanne M., Flam T. et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int: 2011; 107 1411 1418 10.1111/j.1464-410X.2010.09808.x
28. Bloch B. N., Furman-Haran E., Helbich T. H. et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging - initial results. Radiology: 2007; 245 176 185 2451061502 [pii] 10.1148/radiol.2451061502 (Pubitemid 47417801)
29. Cirillo S., Petracchini M., Scotti L. et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol: 2009; 19 761 769 10.1007/s00330-008-1174-8
30. Scheenen T. W., Futterer J., Weiland E. et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol: 2011; 46 25 33
31. Turkbey B., Mani H., Shah V. et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol: 2011; 186 1818 1824 10.1016/j.juro.2011.07.013 S0022-5347(11)04362-X [pii]
32. Coakley F. V., Kurhanewicz J., Lu Y. et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology: 2002; 223 91 97 (Pubitemid 34258194)
33. Rothke M., Blondin D., Schlemmer H. P. et al. PI-RADS-Klassifikation: Strukturiertes Befundungsschema fur die MRT der Prostata. Fortschr Röntgenstr: 2013; 185 253 261 10.1055/s-0032-1330270
34. Portalez D., Mozer P., Cornud F. et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol: 2012; 62 986 996 10.1016/j.eururo.2012.06.044 S0302-2838(12)00757-9 [pii]
35. Schimmoller L., Quentin M., Arsov C. et al. Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol: 2013; 10.1007/s00330-013-2922-y
36. Rosenkrantz A. B., Kim S., Lim R. P. et al. Prostate Cancer Localization Using Multiparametric MR Imaging: Comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert Scales. Radiology: 2013; radiol.13122233 [pii] 10.1148/radiol.13122233
37. Quentin M., Schimmoller L., Arsov C. et al. 3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization. Acta Radiol: 2013; 0284185113492972 [pii] 10.1177/0284185113492972
38. de la Taille A., Antiphon P., Salomon L. et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology: 2003; 61 1181 1186 S0090429503001080 [pii] (Pubitemid 36693999)
39. Eskicorapci S. Y., Baydar D. E., Akbal C. et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol: 2004; 45 444 448; discussion 448-449 10.1016/j.eururo.2003.11.024 S0302283803006353 [pii] (Pubitemid 38376201)
40. Wefer A. E., Hricak H., Vigneron D. B. et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol: 2000; 164 400 404 S0022-5347(05)67370-3 [pii] (Pubitemid 30481935)
41. Durmus T., Reichelt U., Huppertz A. et al. MRI-guided biopsy of the prostate: correlation between the cancer detection rate and the number of previous negative TRUS biopsies. Diagn Interv Radiol: 2013; 19 411 417 10.5152/dir.2013.13055
42. Bodelle B., Naguib N. N., Schulz B. et al. 1.5-T magnetic resonance-guided transgluteal biopsies of the prostate in patients with clinically suspected prostate cancer: technique and feasibility. Invest Radiol: 2013; 48 458 463 10.1097/RLI.0b013e31827c394b
43. Wolter K., Decker G., Willinek W. A. Transperineal MR-guided stereotactic prostate biopsy utilizing a commercially available anorectal biopsy device. Fortschr Röntgenstr: 2013; 185 116 120 10.1055/s-0032-1330549
44. Beyersdorff D., Winkel A., Hamm B. et al. MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology: 2005; 234 576 581 10.1148/radiol.2342031887 (Pubitemid 40139933)
45. Hambrock T., Somford D. M., Hoeks C. et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol: 2010; 183 520 527 S0022-5347(09)02657-3 [pii] 10.1016/j.juro.2009.10.022
46. Hoeks C. M., Schouten M. G., Bomers J. G. et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol: 2012; 62 902 909 10.1016/j.eururo.2012.01.047 S0302-2838(12)00123-6 [pii]
47. Roethke M., Anastasiadis A. G., Lichy M. et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol: 2012; 30 213 218 10.1007/s00345-011-0675-2
48. Puech P., Rouviere O., Renard-Penna R. et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy - prospective multicenter study. Radiology: 2013; 268 461 469 10.1148/radiol.13121501 radiol.13121501 [pii]
49. Durmus T., Stephan C., Grigoryev M. et al. Detection of prostate cancer by real-time MR/ultrasound fusion-guided biopsy: 3T MRI and state of the art sonography. Fortschr Röntgenstr: 2013; 185 428 433 10.1055/s-0032-1330704
50. Sonn G. A., Chang E., Natarajan S. et al. Value of Targeted Prostate Biopsy Using Magnetic Resonance-Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen. Eur Urol: 2013; S0302-2838(13)00249-2 [pii] 10.1016/j.eururo.2013.03.025
51. Walton-Diaz A., Hoang A. N., Turkbey B. et al. Can MR-US Fusion Biopsy Improve Cancer Detection in Enlarged Prostates? J Urol: 2013; S0022-5347(13)04619-3 [pii] 10.1016/j.juro.2013.05.118
52. Lees K., Durve M., Parker C. Active surveillance in prostate cancer. Current Opinion in Urology: 2012; 22 210 215 10.1097/MOU.0b013e328351dc47
53. Wise A. M., Stamey T. A., McNeal J. E. et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology: 2002; 60 264 269 S0090429502017284 [pii] (Pubitemid 34831770)
54. de la Rosette J., Ahmed H., Barentsz J. et al. Focal therapy in prostate cancer-report from a consensus panel. Journal of endourology/Endourological Society: 2010; 24 775 780 10.1089/end.2009.0596
55. Bomers J. G., Sedelaar J. P., Barentsz J. O. et al. MRI-guided interventions for the treatment of prostate cancer. Am J Roentgenol: 2012; 199 714 720 199/4/714 [pii] 10.2214/Am J Roentgenol.12.8725
56. van den Bos W., Muller B. G., de la Rosette J. J. A randomized controlled trial on focal therapy for localized prostate carcinoma: hemiablation versus complete ablation with irreversible electroporation. Journal of endourology/Endourological Society: 2013; 27 262 264 10.1089/end.2013.1568